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1. Introduction 
1.1. Host-pathogen interaction: A process of co-evolution 
In the mind of most human beings, microbial pathogens, including viruses, bacteria, and 
parasites, are the foreign invaders that cause diseases, and sometimes death. Thus, 
prevention and treatment of infectious diseases, by controlling and eradicating microbial 
pathogens, has become one of the major tasks of modern medicine. Based on current 
evolutionary theory, however, most of the pathogens we’ve seen nowadays are the species 
that have evolved through a close interaction with their hosts (e.g. humans and other 
animals). In an even broader sense, the hosts and the pathogens co-evolved through a 
mutual interaction. During this co-evolution, hosts and pathogens develop specific, intricate 
systems to either defend or invade, which in turn presents us with an intriguing picture of 
host-pathogen interaction. Host cells have the ability to defend themselves against the 
invasion of microbial pathogens. On one hand, host cells use the plasma membrane as a 
physical barrier that prevents pathogens from entering the cytoplasm, leaving pathogens in 
the harsh environment of the extracellular milieu, where pathogens are exposed to anti-
microbial elements, such as antibodies, cytokines, and complement factors. On the other 
hand, professional phagocytic cells can engulf microbial pathogens into the phagosomes 
that later fuse with lysosomes, where reactive oxygen species (ROS), low pHs, and proteases 
can inactivate and kill the pathogens. Through the course of evolution, however, pathogens 
have developed effective strategies against such host defense systems. Viruses and obligate 
intracellular bacterial and protozoan pathogens gain access into phagocytic and non-
phagocytic cells through membrane remodeling events, such as phagocytosis and 
macropinocytosis. In many cases, these membrane-remodeling events are controlled by 
cytoskeletal rearrangement mediated by pathogen-produced effector proteins (e.g. toxins) 
[1-3]. Within the phagosomes, pathogens have evolved a variety of mechanisms to protect 
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themselves from damage by the hostile environment. For instance, pathogens can produce 
effector proteins to antagonize ROS effects [4], inhibit phagosome maturation, block 
phagosome-lysosome fusion, and escape from phagosomes [5]. In contrast, extracellular 
pathogens need to protect themselves from being engulfed by professional phagocytic cells. 
Such pathogens usually produce toxins to disarm the host cell defense, resulting in 
inhibition of phagocysis, or in cell killing [6]. Some bacterial toxins are directly translocated 
into the host cytoplasm through sophisticated ‘molecular syringes’, such as type III or type 
IV secretion systems [7-9], which are multi-subunit molecular machines that span the 
bacterial and host membranes and translocate effectors directly into host cells. Other toxins 
(e.g. AB toxins) are secreted by bacteria in the vicinity of the host cell and these toxins bind 
to specific receptors and are taken up by endocytosis [10-13]. Once internalized, bacterial 
toxins usually take advantage of the hostile environment in endosomes/lysosomes, and they 
hijack host factors, which enables translocation into the cytosol. For instance, many bacterial 
toxins utilize endosomal acidification (low-pH) as a trigger for conformational conversion, 
which activates toxins and/or facilitates release of toxins into the cytoplasm [14]. Moreover, 
some pathogens and toxins hijack cellular redox factors, thus allowing them enter into the 
host cells, which will be discussed in detail in this review. 
1.2. Endocytic pathways: The portals of entry for microbial pathogens and toxins 
Endocytosis is a physiological process of invagination and pinching-off pieces of the plasma 
membranes, and IT serves as a ubiquitous mechanism that facilitate the internationalization 
of various particles and molecules from the extracellular milieu into the host cytoplasm. 
Endocytosis plays a vital role in a diverse range of physiological processes, including 
maintenance of cellular homeostasis, cell polarity, and uptake of nutrients. Thus, it is not 
surprising that a great variety of microbial pathogens and toxins have evolved to exploit 
aspects of this internalization process as portals of entry into host cells. Based on the nature 
(e.g. size) of the extracellular substrates, endocytosis has been categorized into phagocytosis 
and pinocytosis. Phagocytosis is involved in engulfment of large particles (e.g. cell debris and 
bacterial pathogens) by professional phagocytic cells, such as macrophages, monocytes and 
neutrophils. Pinocytosis, on the other hand, is typically involved in uptake of small particles, 
such as viruses and bacterial toxins, by non-phagocytic cells. Based on the proteins involved in 
membrane vesiculation, endocytosis is defined by several types of mechanisms, including 
clathrin-mediated, caveolin-mediated, lipid raft-dependent, and macropinocytosis, etc. These 
different mechanisms have been described in recent excellent reviews [6,15-18].  
Despite the diversity of membrane vesiculation, upon endocytosis most pathogens and 
toxins follow one of the two intracellular trafficking pathways (Figure 1). In pathway 1, 
pathogens and toxins travel to the early and late endosomes where some pathogens (e.g. 
HIV, Chlamydia, Leishmania) and toxins (e.g. anthrax toxin, diphtheria toxin, botulinum 
toxin) translocate to the cytosol; while others (e.g. Listeria monocytogenes) travel to the 
lysosomes and are then released into the cytosol. In pathway 2, instead of going through the 
endo-lysosomal pathway, pathogens and toxins (e.g. SV40, cholera toxin, shiga toxin, 
exotoxin A) traffic to the Golgi, and from the Golgi to the endoplasmic reticulum (ER), a 
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pathway in reverse of the classical secretion pathway, called retrograde transport. An ER 
retention signal (e.g. KDEL) is usually required for this transport to occur [10,13,15,16,18,19].  
To date, substantial evidence has suggested that cellular redox factors play an essential role 
in pathogen and toxin entry through endocytosis. These redox factors include protein 
disulfide bond isomerase (PDI), -interferon inducible lysosomal thiol reductase (GILT), 
NADPH oxidases (Nox) and some ER-chaperones. These redox factors function at various 
sites in the endocytic pathways that facilitate pathogen and toxin entry into the cells (Figure 
1). These events will be discussed in detail in the later sections of this review.  
 
 
Figure 1. Interaction of cellular redox factors with microbial pathogens and toxins in the endocytic 
pathways. Microbial pathogens and toxins are internalized into the host cells through endocytosis. 
Pathway 1 (left): The pathogens and toxins travel to endosomes and/or lysosomes where they 
translocate to the cytosol. Pathway 2 (right): the pathogens and toxins undergo retrograde transport 
through Golgi to ER where they are released into the cytosol. In this cartoon, HIV, SV40, Chlamydia, 
Listeria monocytogenes, Leishmania, are presented as the representatives of microbial pathogens that 
are discussed in the review.  A group of AB toxins are also shown in this cartoon, and some of these 
toxins are discussed in this review. The cellular redox factors, such as PDI, GILT, NADPH oxidase 
(Nox), are placed into the various locations of the endocytic pathways according to the current 
literature. Due to space limitation, the cartoon only depicts a simplified illustration. Solid arrows: 
intracellular trafficking; dashed arrows: translocation across the membranes. 
 
Molecular Regulation of Endocytosis 64 
1.3. Disulfide bond: A redox-controlled switch for pathogen and toxin entry   
Disulfide bond, a covalent link between a pair of cysteine residues, plays important roles in 
protein structure and function. Disulfide bond has a significant impact on thermodynamics 
of protein folding, as it can stabilize the native conformation by disfavoring the unfolded 
form. In a naturally folded protein, disulfide bond maintains the protein’s integrity by 
protecting the protein from damage by oxidants and proteolytic enzymes [20-23]. More 
importantly, in mature, folded proteins, some disulfide bonds can function as molecular 
switches that can turn “on” or “off” certain protein functions. This is usually accomplished 
via conformational changes induced by breaking, forming, or the isomerization of the 
disulfide bonds [24-26]. These diverse, reversible features of disulfide bonds can be readily 
manipulated by redox factors ranging from small molecular reagents (e.g. reduced/oxidized 
glutathione) to macromolecular redox enzymes (e.g. oxidoreductases). Moreover, these 
redox factors are ubiquitously present, yet un-equally distributed in the sub-cellular 
compartments of eukaryotic cells, which offers a distinct spatial regulation of the 
thiol/dithiol equilibrium [27,28]. In the course of evolution, microbial infection has become a 
highly regulated process. Thus, activation at the right time and at the right location is an 
important factor for pathogens and toxins to successfully cause an infection. Thus, a readily 
controlled disulfide bond “on/off” switch is evolutionarily favored. It is not surprising that 
pathogens and toxins use disulfide bonds as redox-controlled switches for invasion.  
Increasing evidence has shown that cellular redox factors play pivotal roles in pathogen and 
toxin entry into the endocytic pathways, particularly through modulating the thiol-dithiol 
states of pathogen- and/or host-factors. For instance, cellular entry of certain bacterial toxins 
(e.g. diphtheria toxin [29-33], cholera toxin [34], botulinum neurotoxins [35,36], anthrax 
toxin [37]) are apparently dependent on the redox states (either reduced or oxidized) of the 
specific disulfides of either the toxin molecules, or the host receptors. At the same time, 
protein disulfide isomerase (PDI) [38] and other redox factors, such as gamma-interferon-
inducible lysosomal thiol reductase (GILT)  [39]) and NADPH oxidase [40-42], have been 
implicated in regulating the redox states of the disulfides. Similarly, PDI and others are also 
involved in the entry of numerous pathogenic bacteria (e.g. Chlamydia [43,44], Listeria [39]), 
viruses (e. g. HIV [45] and SV40 (46,47]) and parasites (e. g. Leishmania [40]) through 
endocytosis. This review will present the current major findings on the roles of cellular 
redox factors in pathogen and toxin entry with an attempt to outline the strategies and 
mechanisms that microbial pathogens and toxins utilize to hijack the cellular redox factors 
within the endocytic pathways.  
2. Cellular redox factors in endocytic pathways 
2.1. Redox potentials of endocytic pathways: Oxidizing or reducing? 
Eukaryotic cell is organized into several distinct sub-cellular compartments, each of which 
maintains a distinct redox potential [28]. Relative to the extracellular milieu, which is 
oxidizing, it is generally believed that endocytic pathways are reducing. This notion is based 
on the primary function of endocytosis: i.e., the uptake and degradation of foreign and self-
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particles including proteins, for which a reducing potential facilitates protein unfolding.  
This concept has been well supported by the evidence that uptake and activation of some 
bacterial toxins, such as diphtheria toxin, cholera toxin and Pseudomonas exotoxin A, through 
the endocytic pathways involves reduction of disulfides. The dynamics of disulfide reduction 
in endocytic pathways have recently been studied with fluorescence resonance energy transfer 
(FRET) using a fluorescent folate conjugate, in which folate-BODIPY and Rhodamine is linked 
with a disulfide bond [48]. Reduction of this disulfide bond changes fluorescence from red to 
green, which allows real-time fluorescence imaging of the reduction in cells. Reduction was 
observed to occur in endosomes, with a half-life of 6 hours post-endocytosis. Using this 
experimental setup, reduction did not depend significantly on extracellular surface thiols or 
redox machinery within lysosomes or Golgi. The yielded products were sorted into different 
endosomes and trafficked in different directions. This excellent FRET design ensures an 
accurate assessment of disulfide bond reduction during normal vesicle trafficking in living 
cells and demonstrates that reduction occurs in the endocytic pathways. In fact, the presence of 
distinct redox potentials between the oxidizing extracellular space and the reducing endocytic 
pathways has created interest in disulfide bonds as a potential tool for drug delivery. For 
example, the disulfide-based bioconjugation approach has become a popular conjugation 
method applied in a variety of cellular drug delivery systems. Successful applications of thiol-
based conjugation resulted in targeted delivery and enhanced cytosolic delivery, improved 
pharmacokinetics, and increased stability of the drugs [49-52].  
While it is generally accepted that endocytic pathways are reducing, there is also evidence 
suggesting the contrary. In another independent study, a disulfide linker cleavage assay was 
developed whereby rhodamine red was linked to an anti-HER2 antibody through a peptide 
linker containing a disulfide bond [53]. Cleavage of the disulfide bond would release self-
quenching of the fluorophore. In breast carcinoma SKBr3 cells, no linker cleavage was 
observed, as detected by fluorescence dequenching upon internalization. In contrast, the 
conjugate did display fluorescence dequenching when it was diverted to the lysosomal 
pathways, which could be an effect partly due to proteolytic degradation rather than 
disulfide reduction. More convincingly, the redox potentials of endocytic compartments 
were measured directly by expressing a redox-sensitive variant of GFP fused to various 
endocytic proteins. The results showed that recycling endosomes, late endosomes, and 
lysosomes were not reducing, but rather oxidizing and to a level comparable with 
conditions in the ER.  
In summary, the redox potentials in the endocytic pathways appear to vary accordingly to 
different ligands, different cell types, and different physiological/pathological conditions. 
For instance, NADPH oxidase, the major enzyme that catalyzes the production of reactive 
oxygen species (ROS), is regulated by hormone or growth factors in normal cells, but it is 
constitutively activated in cancerous cells such as HeLa and hepatoma cells [54]). It is well 
known that in professional phagocytic cells NADPH oxidase is activated upon pathogen 
infection and that it produces ROS within the phagosomes, a process called oxidative burst 
that is described below.  
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2.2. Oxidative burst and NADPH oxidase in professional phagocytic cells 
When professional phagocytes recognize pathogen-associated molecular patterns that are 
located on microbial pathogens, the phagocytes will internalize them through phagocytosis 
and activate a strong bacterial killing mechanism, called oxidative or respiratory burst, 
which is marked as an abrupt increase of superoxide formation within the phagosomes [55]. 
This process is mainly catalyzed by NADPH oxidase, a membrane-associated enzyme 
complex that is located on the phagosome membrane and generates superoxide (O2-) by the 
one-electron reduction of oxygen, using NADPH as the electron donor. Assembly and 
activation of NADPH oxidase requires phosphorylation of its subunits and translocation of 
cytosolic components to the plasma membrane [56,57]. The superoxide anion generated is 
enzymatically converted to hydrogen peroxide by superoxide dismutase (SOD). The 
generated hydrogen peroxide can serve as a precursor for hydroxyl radical (OH) 
generation via a Fenton-like reaction. Hydrogen peroxide then enters cells and forms 
hydroxyl radical that can kill many microorganisms by reacting with different 
macromolecules, including proteins and DNA. Except for killing microorganisms directly, 
ROS can also work as secondary messengers in many signaling pathways within phagocytic 
cells, which promote actions of other antibacterial agents and stimulate inflammation. 
However, chronic inflammation induced by ROS may damage the host tissue and induce 
apoptosis of the phagocytic cells [56-58].  
2.3. Protein disulfide isomerizes and other oxidoreductases (e.g. GILT) 
2.3.1. Protein disulfide isomerase (PDI) 
Enzymatic activities and sub-cellular localization: 
PDI is a ubiquitous dithiol/disulfide oxidoreductase chaperone belonging to the thioredoxin 
oxireductase superfamily. There are around 20 PDI homologues, and the structure and 
function of eukaryotic PDIs have been covered in recent excellent reviews [59,60]. The 
prototypic PDI contains 5 domains ordered as a-b-b’-a’-c, in which two thioredoxin-like 
motifs (CXXC) are located in the domains a and a’, respectively. The primary function of 
PDI is to promote protein oxidative folding in the ER. The PDI redox-domains catalyze three 
redox reactions: reduction (breaking disulfide bond), oxidation (forming disulfide bond), 
and isomerization (exchanging disulfide bond). Independently of its redox activity, PDI also 
functions as a chaperone, which requires its ATPase and Ca2+ activities [60-62].  PDI contains 
a KDEL sequence at the domain c, which facilitates its retention in the ER lumen, and PDI 
cycles between ER and cis-Golgi through the KDEL receptor. Despite its KDEL sequence 
and ER retention mechanism, PDI is also involved diverse intracellular trafficking processes 
and is even secreted outside cell and can be found at the cell surface [59]. The cell-surface 
PDI is thought to localize on the plasma membrane by attachment to lipids, glycans and 
integral membrane proteins [59,63]. Unlike other members of thioredoxin family, PDI is not 
normally found in the cytosol. In addition to catalyzing protein oxidative folding in the ER, 
PDI has been shown to be actively involved in many other processes, such as ER-associated 
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degradation, trafficking, calcium homeostasis, antigen presentation and host-pathogen 
interaction [60].  
ER-located PDI: 
The ER-located PDI plays an important role in host-pathogen interactions, particularly in 
antigen presentation and ER-mediated phagocysis of intracellular pathogens. Antigen 
presentation occurs through two pathways: the exogenous pathway and the endogenous 
pathway. In the exogenous pathway, the antigens from extracellular pathogens (e.g. fungi, 
bacteria, and parasites) are captured and processed in the phagosome/lysosome 
compartments within the long-lived antigen presenting cells (e.g. macrophages and 
dendritic cells) and then form complexes with MHC class II. The antigen complexed with 
MHC-II is then presented on the cell surface and subsequently recognized by helper CD4+ T 
cells. In endogenous pathway, self cell antigens and viruses synthesized within cells are 
degraded by the proteasome and then form complexes with MHC class I, which are 
presented on the cell surface and recognized by cytotoxic CD8+ T cells.  The two pathways 
sometimes overlap and antigens can be presented by both MHC class I and class II. These 
include some intracellular bacterial and parasite pathogens that pass or live in the 
phagosomes, such as salmonella typhimurium, Mycobacterium tuberculosis, Leishmania spp and 
Trypanosoma cruzi. As a part of the protein folding machinery in the ER, PDI has been shown 
to directly regulate antigen processing of the MHC class I complex [64,65] .  
Phagocysis is the main mechanism for the professional phagocytes to internalize large 
pathogens. A recent study has found that fusion of the ER with the plasmalemma 
underneath phagocytic cups is a source of membranes for the phagosome formation within 
macrophages. The ER-associated chaperones, including PDI, are involved in this intense 
membrane remodeling process [66,67]. Of particular interest to this review article is the ER-
associated PDI that is involved in the translocation of the toxins (e.g. cholera toxin) and 
pathogens (e.g. SV40 and Leishmania) from the ER to the cytosol.  
Secreted and cell-surface associated PDI: 
While PDI enzymes are predominantly located in the ER where they act as chaperones and 
facilitate protein folding, they also can be secreted extracellularly and located on the cell 
surface. The secreted PDI and the cell surface PDI can be identified by the use of antibodies 
or specific ligands. Since PDI is a soluble protein, PDI is associated with the cell surface 
probably through electrostatic interaction with other surface-located proteins, peptides or 
lipids. The thioredoxin sites of PDI appear to be involved in the reducing activity of the cell 
exterior where protein disulfide bonds are reduced or reshuffled. Recent research has shown 
that the level of cell surface thiols positively correlates to the amount of cell surface PDI (68). 
Consistent with the fact that the thiol groups of cell surface proteins are involved in cell 
adhesion, PDI thioredoxin activity plays an important role in cell adhesion. In leukocyte 
adhesion, PDI reducing activity maintains the adhesion protein L-selectin in a particular 
conformation (disulfide breaking) on the cell membrane that is not accessible to proteolytic 
enzymes. Inhibition of PDI leads to a conformational change in L-selectin (disulfide 
forming), and the subsequent cleavage of L-selectin, which results in lose of cell adhesion 
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[22]. PDI is also involved in the integrin-mediated platelet adhesion. Integrin receptors 
contain “open” and “close” conformations that represent the “on” and “off” states of ligand 
binding, respectively. It has been suggested that PDI regulates the open and close 
conformations through reduction and/or reshuffling of the disulfide bonds in integrins 
[23,69,70]. The cell-surface PDI not only plays important roles in physiological processes, it 
is also involved in pathological events, particularly in the entry of pathogens and toxins into 
host cells as discussed in detail in this review.  
PDI regulation of NADPH oxidase: 
NADPH oxidase is not only the main source of ROS production during oxidative burst, it 
also has been described as another cell surface-associated protein with disulfide–thiol 
interchange activity [54,71]. NADPH oxidase proteins on the mammalian cell surface exhibit 
two different activities, oxidation of hydroquinones (or NADH) and protein disulfide-thiol 
interchange. Protein thiols on the membranes were measured by reaction with 5,5'-dithiobis-
(2-nitrobenzoic acid) (DTNB; Ellman's reagent) and the results suggested that protein 
disulfides may be the natural electron acceptors for NADH oxidation within plasma 
membrane vesicles. Protein disulfides of the membranes were reduced, with a concomitant 
stoichiometric increase in protein thiols in the presence of NADH, while the increase in 
protein thiols was inhibited in parallel to the inhibition of NADH oxidation.  
It is not clear how NAD(P)H oxidase catalyzes disulfide-thiol exchange. Interestingly, PDI 
has been shown to regulate NAD(P)H oxidase activity. In rabbit aortic smooth muscle cells 
PDI was found to be co-localized and co-immunoprecipitated with the oxidase subunits p22, 
Nox1, and Nox4. Inhibition of PDI using PDI antagonism, such as bacitracin, scrambled 
RNase, neutralizing antibody, or antisense oligonucleotide, resulted in inhibition of the 
oxidase activity, which suggests that PDI closely associates with NAD(P)H oxidase, and acts 
as a novel redox regulator of the oxidase [72]. Later, the PDI-mediated regulation of 
NADPH oxidase activity was confirmed, showing that PDI plays a role in organizing 
NADPH oxidase activation in a variety of physiological/pathological events [41,42,73], of 
which PDI association with NADPH oxidase is required for phagocytosis of Leishmania 
chagasi promastigotes in macrophages as is discussed later in this review.  
2.3.2. Gamma-interferon (IFN-γ)-inducible lysosomal thiol reductase, GILT 
Proteins internalized via the endocytic pathways are usually degraded in lysosomes, where 
proteolysis is facilitated by protein denaturation induced by acidic condition and by 
reduction of inter- and intra-molecular disulfide bonds. While high concentration of 
cysteines was claimed to be the physiological reducing agent in lysosomes, this small 
molecular reducing agent alone appears inefficient in disulfide reduction in an acidic 
environment, since disulfide reduction requires deprotonantion of thiols, which is not 
favored by acidic environments. Thus, the presence of redox enzymes within the acidic 
cellular compartments had been postulated for a long time [74,75]. Known redox enzymes, 
such as thioredoxin reductase and glutathione reductase, normally function in neutral pH 
environments, so they are obviously not the likely candidates. The enzymes that catalyze the 
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reduction within acidic compartments had been elusive until recently when GILT was 
identified as the first thiol reductase optimally active at low pH (4.0 – 5.5) [76,77]. GILT is 
expressed constitutively in antigen-presenting cells, in which it is synthesized as a 35-kDa 
glycoprotein precursor containing a mannose-6-phosphate signal sequence and is co-
localized with early endosomes. The amino- and carboxyl-terminal propeptides are cleaved 
in the early endosomes and the 30-kDa mature enzyme is delivered by the mannose 6-
phosphate receptors through the endocytic pathways to late endosomes and lysosomes. The 
mature enzyme is found in MHC class II-containing compartments, where it catalyzes 
disulfide bond reduction to facilitate antigen processing [78]. GILT can also facilitate the 
transfer of disulfide-containing antigens into the cytosol, enhancing their cross-presentation 
by MHC class I [79]. Compared to other members of the thioredoxin family, GILT possesses 
seminar yet distinctive enzymatic characteristics. GILT has a similar catalytic active site (-C-
X-X-C-), but does not have the common motif (-C-G-H/P-C-) that is shared by the members 
of the thioredoxin family. GILT shows optimal activity at pH 4.0-5.5, while the other 
members of the family function optimally at neutral pH. Moreover, GILT requires a 
reducing agent, such as DTT or cysteine (but not glutathione) to regenerate and retain its 
activity in vitro [76], which is consistent with the potential function of cysteine in the acidic 
compartments for disulfide reduction.  
In addition to being constitutively expressed in antigen presenting cells, GILT is induced 
and up-regulated by interferon-r (IFN-γ) in other cell types via signal transducer and 
activator of transcription 1 [80]. GILT has been found to accumulate in macrophage 
phagosomes as they mature into phagolysosomes [81]. Most interestingly, GILT is a critical 
host factor for Listeria monocytogenes infection [39], as is discussed later in this review.  
3. Roles of redox factors in entry of bacterial toxins through endocytosis 
3.1. AB toxins and interchain disulfide bond 
A number of proteins produced by bacterial pathogens are highly toxic to mammalian cells 
due to their ability to enter the cytosol and attack essential cellular metabolic and/or signal 
transduction pathways. These toxic proteins mostly belong to AB toxin family (82). AB 
toxins contain two structurally and functionally distinctive moieties: an enzymatically active 
A moiety that normally modifies a cellular target upon entry into the cytosol, leading to cell 
death or other pathological effects; and a binding/translocation B moiety that binds to cell 
surface receptors and translocates the A moiety into the cytosol. Commonly, an AB toxin is 
synthesized and secreted from the pathogen as an inactive form. This inactive precursor is 
activated through a proteolytic cleavage performed by either a host or a pathogen protease 
at a region between two cysteine residues. The cleavage results in a di-chain toxin molecule 
with the A moiety and the B moiety linked by a disulfide bond (Figure 2). AB toxin-
mediated intoxication of the host cells starts with B moiety binding to the cell surface 
receptors, followed by receptor-mediated endocytosis. Some toxins, such as anthrax toxin, 
diphtheria toxins, and Clostridial neurotoxins, traffic to endosomes, where acidification 
triggers conformational change on B moiety that forms a protein conductive channel/pore 
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on the endosomal membranes and translocates A moiety into the cytosol. Other toxins, 
including shiga toxin, cholera toxin, exotoxin A, will travel through a retrograde transport 
pathway to arrive at the ER. There, A moiety is released into the cytosol (Figure 1 and 2). In 
either of these two intracellular trafficking schemes, it is presumed that the interchain disulfide 
that links A and B moieties must be cleaved prior to translocation of A moiety into the cytosol. 
While the mechanism of disulfide reduction-dependent translocation is not fully understood, 
and may be toxin-specific, current research has provided evidence that cellular redox factors 
play essential roles in toxin translocation by mediating reduction of the interchain disulfide.   
 
Figure 2. Molecular organization and translocation of AB toxins. Based on molecular organization 
(presence or absence of interchain disulfide bond) and sites of membrane translocation (endosome or 
ER), AB toxins are divided into four groups as indicated in this cartoon, with the representative toxins 
listed in each group. Group 1: the toxins (e.g. diphtheria toxin) are produced as a single-polypeptide 
precursor. Activation requires a proteolytic cleavage to generate a dichain molecule that is linked by an 
interchain disulfide bond. The toxins travel to the endosomes where the B moiety forms a pore on the 
endosomal membranes and translocates the A moiety into the cytosol. Group 2: the A and B moieties of 
the toxins (e.g. anthrax toxin and C2 toxin) are produced as separate proteins. The B moiety is activated 
by proteolytic cleavage and assembles into a heptameric complex that recruits the A moiety. Within the 
endosomes, the B moiety forms a pore on the endosomal membranes and translocates the A moiety into 
the cytosol. While there is no interchain disulfide bond, the disulfide bonds of anthrax toxin receptor 
are required for the toxin translocation, which is discussed in this review. Group 3: The proteolytic 
cleavage occurs in the A moiety of the toxins (e.g. Cholera toxin), resulting in two fragments, A1 and 
A2, that are linked by a disulfide bond. In the ER, A1 is translocated with the assistance of the ER 
machinery (e.g. Sec) to the cytosol, which requires the reduction of the disulfide bond. Group 4: the 
toxins (e.g. exotoxin A) share a similar structural organization with the toxins in Group 1, but 
translocation occurs in the ER, instead of the endosomes.  
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3.1.1. Diphtheria toxin and cell-surface PDI 
Diphtheria toxin (DT) is secreted as a single polypeptide chain of 535 residues (58 kDa) from 
toxigenic strains of Corynebacterium diphtheriae [83]. DT is activated by a proteolytic 
cleavage that is catalyzed by the cellular protease furin, which results in two protomers (DT-
A, 21 kDa; DT-B, 37 kDa) that are linked by a disulfide bridge (Figure 2). DT-A is an ADP-
ribosyltransferase that ADP-ribosylates elongation factor 2 (EF-2) in the cytosol. DT-B is 
responsible for cell binding and translocation of DT-A to the cytosol. The receptor-binding 
domain at the C-terminal half of DT-B binds to the cell surface receptor (heparin-binding 
EGF-like growth factor) and enters the cell through the receptor-mediated, clathrin-
dependent endocytosis. Within the endosomes, the acidic pH triggers a conformational 
change on DT-B, leading to the exposure of the hydrophobic domains and an increased 
tendency to interact with the membrane lipids. Thus, DT-B inserts into the membranes and 
forms a cation-selective channel that translocates DT-A into the cytosol, where DT-A inhibits 
protein synthesis by ADP-ribosylation of EF-2 [84].  
An earlier study showed that membrane-impermeant sulfhydryl inhibitors (DNTB and 
pCMBS) markedly inhibited DT cytotoxicity, an effect that was not due to inactivation of 
unbound DT, inhibition of endocytosis, or impairment of endosomal acidification [32]. This 
indicated that the reductive cleavage of DT’s interchain disulfide bond mediated by the cell 
surface sulfhydryls is required for the DT cytotoxicity. A later independent study of DT-
mediated Vero cell intoxication showed that reduction of the single interchain disulfide 
bond is the rate-limiting step of the entire intoxication process, and this reduction occurred 
only after the toxin had passed through a low pH triggered structural change on DT-B in an 
early endosome [30]. Together, these studies suggested that the reductive activation of DT is 
catalyzed by sulfhydryls that are originally present at the cell surface and through 
vesiculations, become situated at the inner face of nascent endosomes. Sulfhydryl groups 
blocked at the cell surface will remain blocked in primary endosomes whose fluid volume 
still contains inhibitors. More interestingly, specific PDI inhibitors, bacitracin and anti-PDI 
antibodies, effectively inhibited DT-mediated cytotoxicity [33], suggesting that cell-surface 
PDI is involved in the translocation of DT through the reduction of the interchain disulfide 
bond. The PDI-catalyzed reduction appears to be specifically restricted to the site of 
interchain disulfide bond, but not others. In an earlier study, intramolecular disulfide bonds 
were generated in the DT-A domain by introducing double cysteine residues [29]. During 
endocytosis, the interchain disulfide bond was found to be reduced, while the engineered 
intramolecular disulfide bonds remained intact, which inhibited DT-A unfolding and 
membrane translocation. This target-specific reduction of the interchain disulfide bond 
implicates the existence of enzymatic specificity.    
More recently, however, an assay of measuring the in vitro delivery of DT-A from the lumen 
of purified early endosomes to the external milieu has shown that cellular thioredoxin 
reductase activity plays an essential role in the cytosolic release of the DT-A, suggesting that 
other cellular redox enzymes, except for PDI, may also be involved in DT translocation [85].  
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3.1.2. Cholera toxin and ER-located PDI 
Cholera toxin (CT), produced by the bacterium Vibrio cholerae, acts on intestinal epithelial 
cells in mammals to induce massive salt and water secretion, causing severe diarrhea 
[86,87]. CT consists of one A subunit, an ADP-ribosyltransferase that targets heterotrimeric 
Gs proteins, and five B subunits that bind to the cell surface receptor, ganglioside GM1. The 
A subunit is cleaved by a bacterial endoprotease to form two fragments, A1 and A2, that are 
linked by a disulfide bond (Figure 2). Reduction of the disulfide bond is required for 
translocation of A1 fragment from ER to the cytosol, where it ADP-ribosylates Gs. ADP-
ribosylation of Gs results in a constitutive activation of adenylyl cyclase and an increase of 
cAMP levels. The A2 fragment bores through the center of the B subunit ring with a C-
terminal KDEL (Lys-Asp-Glu-Leu) sequence that protrudes outwards.  CT enters cells through 
clathrin-independent endocytic pathways, primarily through the cholesterol-rich plasma 
membrane domain caveolae. The ER retrieval KDEL sequence located on the A2 fragment 
leads the toxin through the retrograde transport pathway from Golgi network to the ER.  
Within the ER the A1 fragment is unfolded, released from the rest of the toxin, and 
translocated across the ER membrane to the cytosol [88]. It has been reported that 
translocation occurs through the Sec61 channel and utilizes ER-associated degradation 
(ERAD), which is a physiological process for retro-translocation of mis-folded proteins into 
the cytosol.  
Although the mechanism of A1 translocation from ER into the cytosol is not clear, it is 
presumed that the toxin in the ER must undergo the following events: subunits must be 
disassembled, the disulfide bond must be reduced, and the A1 fragment must be unfolded 
in order to be translocated through the Sec61 channel. However, the ER is the compartment 
where proteins are folded, assembled and disulfide bonds are formed. This apparent 
paradox has raised the question of how the disassembly and unfolding of the toxin occur in 
such an unfavorable environment. Because of the reported role of PDI in the reduction of the 
interchain disulfide bond of DT, inhibitors of cell-surface PDI, such as bacitracin, DTNB, and 
anti-PDI antibodies, were tested [89,90]. In contrast to DT, these inhibitors had no effect on 
CT cytotoxicity in intact cells, suggesting that the reduction of CT does not occur at the cell 
surface or in the early endocytic pathways. In the presence of Triton X-100, however, these 
inhibitors significantly inhibited CT activity. Further study revealed that the A1 fragment is 
co-localized with PDI in the ER-derived membrane fraction, suggesting that PDI is the redox 
factor that catalyzes the CT reduction at the ER [90]. Subsequently, an excellent study 
showed that protein disulfide isomerase (PDI) in the ER lumen functions to disassemble and 
unfold the toxin once the A chain is cleaved [34]. In this reaction PDI acts as a redox-driven 
chaperone: that is, in the reduced state, it binds to the A chain and unfolds it, while in the 
oxidized state it releases the substrate. Moreover, the PDI-mediated CT translocation in the 
ER appears to be coordinated with a series of ER proteins, such as Ero1, Erp72, and Derlin-1 
[34,91]. Together, these studies have revealed a highly coordinately operations exploited by 
PDI and other ER chaperone proteins in CT translocation.  
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3.2. Membrane translocation of Botulinum neurotoxins and anthrax toxin: two 
stories without cellular redox enzymes? 
3.2.1. Botulinum neurotoxins: Interchain disulfide bridge remains intact throughout the 
translocation 
Botulinum neurotoxins (BoNTs), produced by various strains of the spore-forming bacteria 
(e.g. Clostridium botulinum, C. butyricum, and C. barati), are known as the most poisonous 
toxins in nature [11,92]. To date, seven antigenically distinguishable BoNTs (designated 
from A to G) have been identified in research. The seven serotypes of BoNTs in combination 
with another neurotoxin of clostridia, tetanus neurotoxin (TeNT) from C. tetani, make up the 
clostridial neurotoxin family. BoNTs cause flaccid paralysis by targeting to peripheral 
motorneuron, while TeNT causes opposite symptoms by acting in inhibitory interneurons 
[82]. Despite their extreme cytotoxicity, when applied with an appropriate dose BoNTs 
could act as effective drugs because of their powerful neuroparalytic activity. In fact, BoNT 
serotype A is the first biological toxin that has received FDA approval for treatment of 
human diseases, such as cervical torticollis, strabismus, and dystonias.  
Each BoNT is synthesized as a ~150 kDa single chain protein. This single chain precursor is 
subsequently cleaved into a di-chain molecule, in which the ~50 kDa light chain (LC) and 
the ~100 kDa heavy chain (HC) remain linked via a single disulfide bond [93,94] (Figure 2). 
The HC is composed of an N-terminal translocation domain and a C-terminal receptor-
binding domain. The receptor-binding domain binds to both gangliosides and protein 
receptors on the cell membrane and the toxin is internalized through a receptor-mediated 
endocytosis [95-97]. Within the acidic endosomes, the translocation domain undergoes a 
conformational change to form a pore on the endosomal membranes and translocates LC to 
the cytosol.  In the cytosol, LC, a zinc endoprotease, specifically cleaves SNARE proteins, 
resulting in inhibition of synaptic exocytosis [13,87,92,98].  
Apparently BoNTs share similar features with DT in terms of molecular organization (e. g. 
The A and B moieties are linked by an interchain disulfide bond) and the mode of entry into 
the host cells (e.g. receptor-mediated endocytosis, low-pH-induced pore formation and 
translocation). Despite of these apparent similarities, however, the interchain disulfide 
bridge of BoNTs appears to dictate a different mechanism in translocation, relative to DT. 
The dynamics of the toxin translocation was elegantly examined in a single channel/single 
molecule assay using patch clamp recording on the cell membranes [36,99]. The disulfide 
bond needs to remain intact throughout LC translocation, and premature reduction of the 
disulfide bond even after channel formation or within the lipid bilayer arrests translocation. 
Consistent with this result, addition of the reducing agent TCEP before the toxin 
endocytosis inhibited the proteolytic activity of BoNT/B in human neuronal SHSY-5Ycells 
(35).  It is hypothesized that the disulfide bridge between LC and HC is intact in the low pH, 
oxidizing environment of the endosomal lumen. Once LC is translocated across the 
membranes, the disulfide bridge is reduced in the neutral pH, reducing cytoplasm, which 
results in LC release [92]. Moreover, in an in vitro planar lipid bilayer system, BoNT can 
conduct the translocation of LC into the trans compartment without the presence of 
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additional cellular factors [10] Together, these results strongly support a model that HC-LC 
complex embedded in the membrane is a transmembrane chaperone. The HC chaperone 
activity driven by a pH gradient across the endosome prevents aggregation of the LC in the 
acidic vesicle interior, maintains the LC in a unfolded conformation during translocation, 
and releases it after it refolds at the neutral-pH cytosol. In this model, the reduction of 
interchain disulfide bond only occurs after the LC translocation to the cytosol [36]. Although 
in planar lipid bilayer, reduction of the disulfide bond occurs without additional factors. 
Presently, it is not clear if any cytosolic redox enzymes facilitate this process in vivo.  
3.2.2. Anthrax toxin: Pore formation and translocation require intact disulfide bonds of the 
receptors 
Anthrax toxin, produced by Bacillus anthracis, is responsible for the major symptoms of 
anthrax disease [14]. Anthrax toxin is a tripartite AB toxin consisting of two A moieties, 
lethal factor (LF, 90 kDa) and edema factor (EF, 90 kDa), and one B moiety, protective 
antigen (PA, 83 kDa). Anthrax toxin-mediated intoxication of host cells starts with PA 
binding to the cell surface receptors. Currently, two receptors for PA have been identified: 
anthrax toxin receptor 1 (ANTXR1; or, tumor endothelial marker 8, TEM8) and anthrax 
toxin receptor 2 (ANTXR2; or, capillary morphogenesis protein 2, CMG2) [101-103]. The 
extracellular domains of the two receptors share over 60% of sequence homology. Both 
contain a conserved von willebrand factor A (VWA) domain, which binds to PA (104), and a 
newly defined immunoglobulin-like (Ig-like) domain [37]. Upon binding to the cell surface 
receptors, PA83 is cleaved by the cellular protease furin into PA63 and PA20. The PA63 self-
assembles into a heptameric or an octameric complex, called prepore, to which LF and EF 
bind. Endocytosis of anthrax toxin is a highly regulated event, in which S-palmitoylation of 
the receptor cytoplasmic tail plays a role to prevent constitutive endocytosis of the toxin. 
The toxin-receptor complex is redistributed on the plasma membrane from the 
glycerophospholipidic regions to the specialized domains of lipid rafts, where receptor 
ubiquitination triggers endocytosis. The toxin-receptor complex is supposedly internalized 
into the cell through the clathrin-mediated endocytosis [12,105,106]. Within the endosomes, 
acidification triggers conformational change on PA and converts the prepore into a pore on 
the endosomal membranes, through which LF and EF are translocated to the cytosol. There, 
LF, a zinc-dependent protease, cleaves MAP kinase kinases, which results in lethality of the 
host cells; EF, an adenylate cyclase, increases cellular cAMP level, which causes edema.  
Unlike many other AB toxins that are produced as a single polypeptide chain and require 
proteolytic cleavage to generate A and B moieties linked by an interchain disulfide bond, 
anthrax toxin is produced as the three separate polypeptides:  PA, LF and EF (Figure 2). 
Most interestingly, anthrax toxin has no cysteine residue out of the total 2373 residues in the 
three proteins. This unique “cysteine-free” feature appears to exclude the possibility of 
exploiting redox-controlled “thiol-dithiol exchange” as a potential mechanism that regulates 
anthrax toxin translocation. However, our recent study showed that the disulfide bonds in 
the Ig-like domain of ANTXR2 were required for anthrax toxin pore formation and 
membrane translocation [37]. Reduction of the disulfide bonds significantly blocked anthrax 
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toxin pore formation on the liposomal membrane and plasma membranes evidenced by the 
release of K+ ion, and it also blocked translocation of a model substrate across the cell 
membranes. More recently, purified PDI was shown to facilitate the refolding of the 
recombinant extracellular domain of ANTXR2 (Sun, unpublished data), indicating that the 
receptor disulfide bonds may be subjected to redox regulation by PDI or PDI-like 
oxidoreductases. The mechanism of anthrax inhibition induced by reduction of the receptor 
disulfide bonds is not yet fully understood. 
Based on the available data, one can hypothesize that anthrax toxin translocation must 
require an oxidative environment or factors that favor the receptor disulfide bond 
formation, instead of reducing it as of DT, CT and other toxins. But how might the 
endosomes maintain a disulfide bond favorable environment? In the early stage of anthrax 
infection, macrophages are activated by the components of Bacillus anthracis and launch a 
strong oxidative burst within the phagosomes for bacterial killing immediately after 
phagocytosis of bacteria [4]. In addition, it is reported that anthrax is expressed and plays an 
essential role in several stages of infection, including the very early stage, in the newly 
germinated spores within macrophages [107,108]. An earlier study has also shown that 
anthrax lethal toxin stimulated an oxidative burst in macrophages and induced cytolysis 
[109]. The toxin-induced macrophage lysis was dependent on the ability of the macrophages 
to mount an oxidative burst and was inhibited by exogenous antioxidants. Based on the 
above evidence and given the fact that anthrax toxin requires a redox environment that 
favors receptor disulfide bond formation for translocation, an intriguing hypothesis is that 
the bacterium and the toxin stimulate an oxidative burst within the host cells so as to ensure 
anthrax toxin translocation. Consistent with this hypothesis, B. anthracis has evolved 
mechanisms defending itself against oxidative stress, including superoxide dismutases, 
peroxidases, and catalases, all of which suppress the damaging Fenton reaction catalyzed by 
reactive oxygen or nitrogen species [4,110,111]. Moreover, as mentioned above, the unusual 
“cysteine-free” feature of anthrax toxin might have been selected through evolution 
permitting the toxin to be exempt from the damaging thiol-modifications caused by 
oxidative stress. In summary, Bacillus anthracis and anthrax toxin may have evolved the 
ability to subvert oxidative burst, the host defense mechanism, for their own benefit. Instead 
of being damaged by oxidative burst, anthrax toxin takes advantage of its oxidizing power 
that maintains integrity of the receptor disulfide bonds for toxin translocation.  
3.3. Thiol-activated cytolysins and GILT: Reduction of undecapeptide cysteine 
Thiol-activated cytolysins are a group of pore-forming toxins that are secreted by 
taxonomically diverse species of gram-positive bacteria, responsible for life-threatening 
infections [112]. Currently, over 20 family members have been identified, including 
listeriolysin O (LLO) from Listeria monocytogenes that causes meningitis and abortion; 
perfringolysin O (PFO) from Clostridium perfringens that causes gas gangrene; and 
pneumolysin (PLY) from Streptococcus pneumoniae that causes pneumonia and meningitis. 
Each of these toxins is produced as a single polypeptide chain with molecular weight 
ranging from 50 – 80 kDa and shares high degree of sequence similarity ranging from 40 – 
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80%, suggesting a close structural and functional relation between them.  In deed, the toxins 
share a common mode of action.  All of the thiol-activated cytolysins are produced as water-
soluble monomers and use cholesterol as cell surface receptors. Upon binding to the 
cholesterol, these toxins undergo cholesterol-dependent oligomerization and membrane 
insertion, leading to membrane damage. Thus, they are also referred to as cholesterol-
dependent cytolysins, CDCs. The diameters of the ring-shaped pores can exceed 150 Å, 
making these toxins a widely used tool as membrane-permeabilizing agents in cell biology. 
Not surprisingly, all the available crystal structures of the toxins share an elongated, four-
domain structure. Upon pore formation, the toxins undergo dramatic domain 
rearrangements that have been recently revealed by excellent fluorescence measurements 
and by cryo-electronic microscopy study [113-115].  
Thiol-activated cytolysins share another critical common feature, that is, the toxins are 
activated by reducing agents and suppressed by oxidation [116,117]. The requirement of 
thiol-reduction for the toxin activation appears to rely on a single cysteine residue located in 
a highly conserved undecapeptide (also known as tryptophan-rich region) in domain 4 of 
the toxins [118,119]. The undecapeptide cysteine is the only cysteine present in the primary 
structure of the secreted toxins. Irreversible oxidation of this cysteine inhibited cytolytic 
activity, suggesting that this cysteine plays a central role in the cytolytic mechanism. Recently, 
GILT was found to be a critical host factor for Listeria monocytogenes infection [39]. As an 
intracellular pathogen, L. monocytogenes is internalized into the phagosomes, where it secrets 
LLO to form pores on the endosomal membranes that facilitate bacterial escape from the 
phagosomes to the cytosol. Since LLO activation requires reducing activity, the authors 
speculated that GILT, the only known thiol oxidoreductase present in the phagosomes, might 
activate LLO in vivo. The results confirmed the authors’ hypothesis, showing that mice lacking 
GILT are resistant to L. monocytogenes infection; GILT activates LLO within the phagosomes by 
the thiol reductase activity and purified GILT activates recombinant LLO in vitro.  
While the thiol(s) targeted by GILT was not directly identified, the highly conserved, 
undecapeptide cysteine is obviously the potential target. Besides LLO, GILT also activates 
streptolysin O (SLO), produced by Streptococcus pyogenes, as measured by the haemolysis of 
sheep red blood cells. But GILT failed to activate the SLO mutant that lacked the 
undecapeptide cysteine residue. Thus, GILT presumably targets to the characteristic 
cysteine residue and GILT-mediated exposure of this critical cysteine may result in a 
conformational change that allows the formation of the pre-pore complex and full 
activation. 
4. Cellular entry of pathogenic bacteria, viruses, and parasites that 
require cellular redox factors 
Available evidence has indicated that cellular redox factors are widely involved in entry of 
numerous microbial pathogens, ranging from bacteria, viruses and parasites. Here, we 
briefly review the best-characterized examples from each category.  
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4.1. Pathogenic bacteria: Chlamydia entry 
Chlamydia trachomatis is the leading bacterial agent responsible for sexually transmitted 
diseases. Two biovariants of C. trachomatis, trachoma and lymphogranuloma venereum, 
cause 90 million new sexually transmitted infections per annum and 400 – 600 million cases 
of trachoma worldwide. As an obligatory intracellular pathogen, it requires host invasion 
for survival and growth. However, little is known about the molecular mechanism of 
Chlamydia entry into host cells. Serovar E, an adhesion molecule from C. trachomatis, is 
known to be required for invasion of genital epithelial cells, but the host factor(s) required 
for the pathogen entry was not known until PDI was identified as an potential mediator 
[43]. PDI was detected in an earlier immunoprecipitation experiment [120]., in which a 
biotinylated apical membrane protein receptor attached to elementary body (EB) was 
stripped off the surface of HE-1B cells and immunoprecipitated with anti-EB antibodies, 
followed by 2D SDS-PAGE and MALDI MS analysis. During EB attachment, exposure of 
HEC-1B cells to three different inhibitors of PDI reductive activity (DTNB, bacitracin, and 
anti-PDI antibodies) resulted in reduced chlamydial infection. Subsequently, a proteomic 
study of CHO6 cell line [121], a mutagenized cell line resistant to attachment and infection 
by Chlamydia, showed that CHO6 has a defect in processing of the leader sequence of PDI, 
which results in altered cellular distribution of PDI. PDI is abundantly localized in the ER, 
and surface localization is predominantly sequestered to large patches compared to the 
punctate pattern in the wild type CHOK1 cells. Complementation by expression of full-
length PDI restored C. trachomatis binding and infectivity in the CHO6 mutant cell line. 
These data directly demonstrate that native PDI at the cell surface is required for effective 
chlamydial attachment and infection. Most recently, RNA interference was used to confirm 
that cellular PDI is essential for Chlamydial attachment to cells [44]. More precisely, the role 
of PDI in the process of chlamydial infection was further dissected using genetic 
complementation and PDI-specific inhibitors, showing that PDI has two essential and 
independent roles in the process of chlamydial infection. It is structurally required for 
chlamydial attachment, and the thiol-mediated oxido-reductive function is necessary for 
entry. While PDI is required for chlamydial attachment, it does not function as a receptor for 
the pathogen. Other host factor(s) that structurally associate with PDI may be required for 
chlamydial attachment.  
4.2. Viral entry 
As obligatory intracellular parasites, viruses can only replicate within host cells. Most 
viruses that infect vertebrate and insect cells exploit the endocytic pathways to enter the 
host cells, particularly through macropinocytosis [15,16]. Entry of enveloped virus to the 
host cells normally requires binding of virus to the cell surface and fusion of the viral 
membrane with the host cell membrane. These processes are accomplished through a 
coordinated interaction between viral envelope glycoproteins and host cell surface 
receptors, during which conformational changes of the proteins involved play an essential 
role in virus binding and/or membrane fusion. Increasing evidence suggests that the 
conformational changes are largely triggered by isomerization or reduction of the disulfide 
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bonds catalyzed by either viral- or host- redox factors. The requirement of redox factors for 
viral entry is exemplified with human immunodeficiency virus (HIV), Newcastle disease 
virus [122-124], Sindbis virus [125] and avian leukosis virus [126], etc. For the non-
enveloped virus SV40, the virus is internalized through endocytosis and retrograde 
transported to ER, where it makes use of the thiol-disulfide oxidoreductases, ERp57 and PDI 
as well as the retrotranslocation proteins, to move to the cytosol. The HIV and SV40 viruses 
are discussed below. 
4.2.1. HIV 
Infection of human immunodeficiency virus (HIV) starts with viral binding to attachment 
factors, such as mannose binding C-type lectin receptor and intracellular adhesion molecule 
on the surface of CD4+ lymphocytes. The HIV envelope glycoprotein gp120 binds to CD4 
protein, the primary receptor of HIV-1, and undergoes conformational changes, which 
allows the virus to interact with its co-receptors, CXCR4 or CCR5. Subsequently, these 
interactions stimulate downstream conversion of HIV gp41 envelope subunit to a competent 
fusion conformation [45]. Initially, inspired by the finding that the cell-surface PDI reductive 
activity is required for DT entry and cytotoxicity through reduction of the interchain 
disulfide bond, the roles of cell-surface PDI in HIV entry into human lymphoid cells were 
tested with PDI inhibitors, DTNB, bacitracin and anti-PDI antibodies [127]. The result 
showed that HIV infection was markedly inhibited by those inhibitors, suggesting that HIV 
and its target cell engage in the PDI-mediated thiol-disulfide interchange and that the 
reduction of critical disulfides in viral envelope glycoproteins may be the initial event that 
triggers conformational changes required for HIV entry and cell infection. This finding 
revealed a novel direction in the study of HIV entry. A series of experiments have been 
performed to define the roles of PDI or PDI-like redox enzymes in viral entry and 
membrane fusion, particularly in the aspect of thiol-disulfide interchange on viral- and host- 
factors. PDI was first found clustered at the CD4+ lymphocyte surface in the vicinity of CD4-
enriched regions and later PDI was co-precipitated with both soluble and cellular CD4 [128]. 
Moreover, anti-PDI antibodies and the inhibitors of its catalytic function altered HIV 
envelope-mediated membrane fusion, which suggests that PDI catalytic activity functions in 
the HIV envelope-mediated cell-cell fusion in a post-CD4 binding step [129]. It is believed 
that PDI-CD4 interaction at the cell surface enables PDI to reach CD4-bound viral 
glycoproteins. HIV gp120 is a highly disulfide-bonded molecule that attaches HIV to CD4 
and co-receptor CXCR4 or CCR5, thus it becomes a potential target of cell-surface PDI. It has 
been shown that soluble PDI cleaved disulfide bonds in the recombinant gp120 in vitro and 
the gp120 bound to the CD4 on the cell surface undergoes a disulfide reduction that is 
prevented by the PDI inhibitors [130]. Furthermore, additional studies showed that on 
average two of the nine disulfides of gp120 are reduced during interaction with the 
lymphocyte surface after CXCR4 binding prior to fusion and that the cell surface PDI 
catalyzes this process. Thus, the PDI-mediated disulfide restructuring within the HIV 
envelope constitutes the molecular basis of the post-receptor binding conformational 
changes that induce fusion competence. Due to the essential role of PDI in HIV entry, PDI is 
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regarded as a potential drug target. Most recently, a high-throughput screening of PDI-
specific inhibitors identified the natural compound juniferdin as the most potent inhibitor of 
PDI. And derivatives of juniferdin were synthesized and used to carry out further studies, of 
these, compound 13 showed comparable inhibitory activity but reduced cytotoxicity, 
compared to juniferdin [131].   
Interestingly, PDI knockdown by siRNA in U373 and HeLa cells had little effect on HIV 
infection as compared to the effect mediated by general thiol inhibitors [132]. This 
discrepancy raised the question whether the reductive activity of PDI is coupled to other 
redox enzymes that could enhance the redox-dependent viral membrane fusion and entry. 
This hypothesis has been supported by several recent studies. The extracellular portion of 
CD4 contains four immunoglobulin-like domains, D1 to D4. The D2 disulfide bond 
appeared redox-active and regulated by thioredoxin that is secreted by CD4(+) T cells. 
Locking the CD4 and the thioredoxin active-site dithiols in the reduced state with a 
hydrophilic trivalent arsenical blocked entry of HIV-1 into host cells [133]. More recently, 
human glutaredoxin-1 (Grx1) has been shown to efficiently catalyze gp120 and CD4 
disulfide reduction in vitro [134]. Grx1 catalyzes the reduction of two disulfide bridges in 
gp120 in a similar manner to that of PDI. Anti-Grx1 antibodies inhibited the Grx1 activity 
and block HIV-1 replication in cultured peripheral blood mononuclear cells. The polyanion 
PRO2000, previously shown to prevent HIV entry, inhibited the Grx1- and PDI-dependent 
reduction of gp120 disulfides. Thus, other redox enzymes other than PDI may also be 
involved in HIV entry. Studies that further dissect the specific roles of PDI and other redox 
enzymes in HIV entry are needed to uncover the mechanism of HIV entry.  
4.2.2. SV40 
Simian virus 40 (SV40) is a simple, non-enveloped DNA virus that belongs to the polyoma 
virus family. It uses ganglioside GM1 as receptor, and enters host cells through a unique 
endocytic pathway, caveolae/lipid raft-mediated endocytosis [15,47,135]. After 
internalization, instead of trafficking to endosome/lysosome compartments, it traffics into a 
pH-neutral, caveolin-containing endocytic organelle, called caveosome. From there the virus 
moves in noncaveolar vesicles along microtubules to the ER through retrograde transport. 
In the ER, SV40 manages to translocate into the cytosol, and from there it enters the nucleus 
via nuclear pore complexes for viral replication. SV40 capsids are composed of 
homopentamers of the major capsid protein VP1, and VP1 is associated with one of the 
minor structural proteins VP2 or VP3. The virus has icosahedral symmetry and contains 72 
pentamers, of which 12 are five-coordinated and the rest of 60 are six-coordinated. The 
pentamers are linked to each other by the interchain disulfide bonds between the residues 
Cys104. Isomerization of the disulfide bonds in the ER is crucial for the viral uncoating 
process [136-138]. Recent data has shown that SV40 makes use of the protein folding and 
quality control machinery in the ER for initial uncoating and membrane translocation [46]. 
Among all the ER-resident proteins, ERp57 and PDI more specifically regulate SV40 
infection through isomerization of the disulfide bonds. Silencing of ERp57 and PDI 
substantially decreases SV40 infection. In addition, these ERp57 and PDI cooperate with the 
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ER-associated degradation (ERAD) proteins, Derlin-1 and Sel1L, facilitating a Ca2+-
dependent retrotranslocation from the ER to the cytosol.  
4.3. Parasite entry 
4.3.1. PDI, NADPH oxidase and Leishmania entry 
Leishmania, a family of obligate intracellular parasites, causes leishmaniases in millions of 
individuals worldwide [139]. The parasites are transmitted by a variety of species of sand 
flies from two major genera Phlebotomus and Lutzomyia, respectively. The life cycle of 
Leishmania starts with a motile promastigote form in the insect host, in which they attach to 
the midgut wall to avoid being expelled with the blood meal. They later migrate to the 
digestive tract and differentiate into a non-dividing metacyclic form. The metacyclic 
promastimgotes are injected into the mammalian host, enter macrophages and differentiate 
into non-flagellated amastigotes that replicate and persist intracellularly, which provides a 
reservoir for transmission. Entry of promastimgotes into macrophages through 
phagocytosis is a critical step for leishmania infection.  Inside the phagosome and/or 
phagolysosome vesicles, the parasites are exposed to enzymes, antimicrobial peptides, and 
ROS generated by NADPH oxidase activation [140]. Surprisingly, the promastimgotes are 
able to survive in such a stressful environment and differentiate into amastigotes, 
progressing to an active infectious disease. While the mechanism of pathogenesis is still 
elusive, current research has greatly advanced our understanding of the process. It is well 
known that Nox2 oxidase, a prototypic member of the NADPH oxidase family, is activated 
during phagocytosis of Leishmania, and uptake of the parasites is inhibited by antioxidants 
(e. g. catalase) [141]. This suggests that the oxidative stress induced by NADPH oxidase 
activation may have a favorable effect, instead of the expected anti-microbial effect, with 
regard to parasite infectivity. Recently, PDI has been shown to be involved in phagocytosis of 
Leishmania chagasi through regulation of NADPH oxidase, in which PDI was found to closely 
associate with the NADPH oxidase, and inhibitors of PDI (bacitracin, phenylarsine oxide, anti-
PDI antibody) significantly blocked promastigote phagocytosis (40). These results correlate 
well with, and are supported by, the previous findings that proteomic study of macrophages 
showed that PDI is involved in the formation of the phagosomes during phagocytosis of some 
parasites, including Leishmania (66,81). And PDI is closely associated with NADPH oxidase 
and plays an organizer role in NADPH oxidase activation [41,72].  
5. Conclusions and future perspectives 
Current studies have revealed excitingly novel features of host-pathogen interaction. 
Microbial pathogens (bacteria, viruses, and parasites) and bacterial toxins exploit different 
aspects of the endocytic pathways, and hijack cellular redox factors to accomplish entry and 
invasion. Despite the fact that the pathogens and toxins are very diverse, the mechanism 
involved in the infectivity could be readily narrowed down to any of the simple redox 
reactions: reduction, oxidation, or isomerization of the thiol/dithiol groups on proteins from 
either pathogens or hosts. Therefore, these redox reactions could potentially be part of a 
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general mechanism for pathogen and toxin invasion, and this redox-dependent entry 
mechanism can be an attractive target for anti-microbial and anti-toxin drug development. 
The specificity of regulation is supposed to heavily rely on specific interaction of the cellular 
redox factors with the pathogens in a timely and spatial manner in various endocytic 
pathways. Thus far, PDI seems to be involved in many of the pathogen and toxin entry 
events, which is, at least in part, due to its diverse cellular distribution, ranging from the cell 
surface to the ER. Further studies are needed to address this question if other members of 
the PDI family and other ER-residing folding machinery are involved in pathogen and toxin 
entry. It is exciting that GILT was identified as the first oxidoreductase active optimally in 
the acidic compartments. The roles of GILT in entry of pathogens or toxins other than L. 
monocytogenes/LLO warrant further investigation. Finally, some pathogens or toxins can 
survive through the oxidative burst within the phagosomes and even can take advantage of 
this host defense mechanism for invasion. Thus, more studies are needed to look into the 
new insights concerning the role of oxidative burst in host-pathogen interactions. 
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